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ABSTRACT
MicroRNAs (miRNAs) are increasingly seen as important regulators of placental development and 
opportunistic biomarker targets. Given the difficulty in obtaining samples from early gestation and 
subsequent paucity of the same, investigation of the role of miRNAs in early gestation human placenta 
has been limited. To address this, we generated miRNA profiles using 96 placentas from presumed 
normal pregnancies, across early gestation, in combination with matched profiles from maternal plasma. 
Placenta samples range from 6 to 23 weeks’ gestation, a time period that includes placenta from the 
early, relatively low but physiological (6–10 weeks’ gestation) oxygen environment, and later, physiolo-
gically normal oxygen environment (11–23 weeks’ gestation).
We identified 637 miRNAs with expression in 86 samples (after removing poor quality samples), 
showing a clear gestational age gradient from 6 to 23 weeks’ gestation. We identified 374 differentially 
expressed (DE) miRNAs between placentas from 6–10 weeks’ versus 11–23 weeks’ gestation. We see a 
clear gestational age group bias in miRNA clusters C19MC, C14MC, miR-17 ~ 92 and paralogs, regions 
that also include many DE miRNAs. Proportional change in expression of placenta-specific miRNA 
clusters was reflected in maternal plasma.
The presumed introduction of oxygenated maternal blood into the placenta (between ~10 and 
12 weeks’ gestation) changes the miRNA profile of the chorionic villus, particularly in placenta-specific 
miRNA clusters. Data presented here comprise a clinically important reference set for studying early 
placenta development and may underpin the generation of minimally invasive methods for monitoring 
placental health.
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Introduction
The human placenta is a complex, rapidly developing and 
highly regulated organ shared between two genetically unique 
individuals, the mother and her foetus. Its function is vital for 
the transfer of nutrients, gases and wastes between maternal 
and foetal circulations, with dysfunction leading to placental 
insufficiencies and pregnancy complications [1,2]. Essential 
placental functions are mediated by the syncytiotrophoblast, 
large multinucleated cells covering the chorionic villi and 
providing a large surface area for bi-directional exchange of 
molecules between foetal and maternal circulations.
Early development of the human placenta occurs in a 
relatively low, but physiological, oxygen environment due to 
the occluding presence of extravillous cytotrophoblasts 
(EVTs) in the uterine spiral arterioles. The placenta transi-
tions to that which is usually considered a physiologically 
normal, oxygen environment over several weeks from 
10 weeks’ gestation when EVTs become dislodged permitting 
maternal blood to flow into the placental intervillous space 
[1,3]. This period of rising oxygen tension is a critical time for 
placental development, as an appropriate response to the 
accompanying burst of oxidative stress is crucial to the 
ongoing success of the pregnancy [3].
Robust characterization of important regulatory mechan-
isms surrounding normal placental development can give 
insight into pregnancy health, and the potential development 
of pregnancy complications [2,4]. Identification of biomarkers 
of ectopic oxygenation or placental dysfunction leading to 
pregnancy complications is an important step in monitoring 
pregnancy health.
MicroRNAs (miRNAs) are an important class of RNA 
molecules that can help us to understand regulation of devel-
opmental pathways within human tissues. As such they are 
prime targets for biomarker research. miRNAs are short, 
approximately 20–24 nucleotide (nt) lengths of single- 
stranded, non-coding ribonucleic acid (RNA) originating in 
non-coding regions of the genome [5] and comprehensively 
reviewed in Bartel (2018) [6]. They most commonly function 
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as post-transcriptional regulators of gene expression either by 
translational repression or targeted degradation by cleavage of 
mRNA transcripts in the cytoplasm [7,8]. miRNAs target 
mRNA regulatory sequences that are often located in the 3ʹ 
untranslated region (UTR) of the mRNA transcript with 
potential for multiple conserved target sites within a single 
mRNA [5,9]. Approximately half of known mammalian 
miRNAs are found within intergenic regions of the genome, 
with the remaining miRNAs mostly transcribed from the 
open reading frame of other genes, including long non- 
coding RNA (lncRNA) [10–12]. Adding to this complexity, 
miRNA may be transcribed as a single, or polycistronic 
unit [11].
The critical role of the placenta in successful pregnancy is 
clear, and there is also evidence linking developmental pro-
gramming of chronic adult disease such as heart disease, 
diabetes and obesity with the placental phenotype in utero 
[4,13,14]. However, there are currently no non-invasive tests 
to determine which women are likely to develop pregnancy 
complications in routine use, nor is there a comprehensive 
reference set of miRNA expression during early pregnancy 
that can be used for development of pregnancy health bio-
markers. In this study, we performed high-throughput 
sequencing to generate robust miRNA expression profiles 
for 96 placentas and matched maternal plasma samples 
between 6–23 weeks’ gestation, creating a comprehensive set 
of miRNA expression profiles for presumably healthy placen-
tal function. We identified differential miRNA expression 
between 6–10 and 11–23 weeks’ gestation which could reflect 
physiological changes occurring in this important time period. 
Using placenta-associated miRNA clusters found on chromo-
some 14, 19, 13, 7 and X, we also investigated how maternal 




Placental chorionic villous tissue samples were obtained with 
informed, written consent from women undergoing elective 
terminations of otherwise healthy pregnancies. Samples of 
peripheral blood (6–9 mL) were collected from the same 
women into standard EDTA blood tubes at the time of termi-
nation and stored on ice until processed. Whole blood under-
went centrifugation at 800 x g for 15 min at 4°C before plasma 
removal and then spun for a further 15 min. All samples were 
stored at −80°C until further processing. Prior to termination, 
accurate gestational age was determined using transvaginal 
ultrasonography. Termination samples were collected from 
the Pregnancy Advisory Centre (PAC), Woodville, South 
Australia. All placenta samples were assessed for gross mor-
phology before inclusion in the study.
RNA extraction and library preparation
All placenta tissues were collected post termination and pro-
cessed as soon as possible after collection and placed into 
RNALater (Thermo Fisher) within 15 min. Total RNA was 
isolated using a modified protocol of the RNeasy mini plus kit 
(Qiagen, Hilden, Germany) whereby the RW1 buffer, a pro-
prietary component of the RNeasy Kit that eliminates small 
RNAs, is replaced with 100% ethanol. The sample is then 
subjected to size fractionation for small RNAs before sequen-
cing. For plasma, miRNA was isolated from 200 μL plasma 
samples using the QIAGEN miRNA serum/plasma kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions. All samples were stored at −80°C until further 
processing. miRNA real-time qPCR for the assessment of 
haemolysis was conducted by QIAGEN Genomic Services 
(Qiagen, Hilden, Germany). 2 µl RNA was reverse transcribed 
in 10 µL reactions using miRCURY LNA Kit (QIAGEN ver-
sion5). Each RT was performed including an artificial RNA 
spike-in (UniSp6). cDNA was diluted 50 x and assayed in 
10 µl PCR reactions according to the protocol for miRCURY 
LNA miRNA PCR; each miRNA was assayed once by qPCR 
using assays for miR-23a, miR-30 c, miR-103, miR-142-3p, 
and miR-451. In addition to these miRNA assays, the RNA 
spike-ins were assayed. The amplification was performed in a 
LightCycler® 480 Real-Time PCR System (Roche) in 384 well 
plates. The amplification curves were analysed using in-house 
software, both for the determination of the Cq (by the 2nd 
derivative method) and for melting curve analysis.
All placenta samples were genotyped for foetal sex using 
high resolution melt curve analysis of the gene that encodes 
amelogenin. Amelogenin is found on both the X (AMELX) 
and Y (AMELY) chromosomes, the X allele features a 3 bp 
deletion in exon 3 allowing the identification of samples with 
only X chromosomes (female) or X and Y chromosomes 
(male) prior to sequencing. Forward primer 5ʹ- 
CCCTGGGCTCTGTAAAGAATAGTG-3ʹ, reverse primer 5ʹ- 
ATCAGAGCTTAAACTGGGAAGCTG-3. qPCR was per-
formed using SSOFast EvaGreen Supermix (Bio-Rad, CA), 
primers at 250 nM final concentration, 5 ng of DNA per 
reaction, on a Bio-Rad CFX384 Real-Time PCR System. 
Cycling conditions: initial denaturation 98°C 30s, 40 cycles 
of 98°C for 5s and 60°C for 5s. High resolution melt curve 
analysis was performed from 65°C to 85°C with a 0.2°C 
increment every 10s. Melt curve between 65°C and 70°C was 
analysed using Bio-Rad Precision melt software (Bio-Rad, 
CA) to identify sex genotypes. Library preparation and 
sequencing was performed by Qiagen (Valencia, CA) using 
the QIAseq miRNA Library Kit and QIAseq miRNA 48 Index 
IL kits as per manufacturer’s instructions. Amplified cDNA 
libraries underwent single-end sequencing by synthesis 
(Illumina 1.9).
High-throughput sequencing analysis
Alignment and analysis of miRNA sequencing data were 
processed from raw FASTQ files using the bcbio-nextgen pipe-
line [15]. Briefly, adapter detection and trimming were per-
formed using Atropos [16]. Alignment was performed using 
STAR [17] using the human reference genome build 
GRCh3718,(https://www.ncbi.nlm.nih.gov/grc. Quality control 
metrics were assessed using FastQC19 (http://www.bioinfor 
matics.babraham.ac.uk/projects/fastqc/) to check for per base 
sequence quality, sequence length distribution and 
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duplication levels, and summarized using multiQC [20]. 
miRNA were clustered and collapsed using SeqCluster [21], 
and individual miRNAs detected using SeqBuster [15]. 
Annotation was performed using the miraligner [15] with 
miRBase version 21.0 [22,23] (http://www.mirbase.org) as 
the reference database.
Differential expression analysis
All profile and expression analyses were conducted in the R 
statistical environment (v.3.3.2), using the edgeR (v.3.16.5) 
and limma [24] (v.3.30.11) R/Bioconductor packages. edgeR 
[25] was used to filter miRNA with low expression and 
normalize for library composition bias. Batch effects, intro-
duced by sequencing samples in multiple sequencing runs, 
were evident after normalization and corrected using a limma 
batch correction method [24]. All samples were then normal-
ized using the Trimmed Mean of M values (TMM). For 
plasma, log2 transformed counts per million (CPM) were 1 
to 1 paired with placenta data prior to creation of plasma 
figures. Briefly, after creating design matrices for both wanted 
(gestational age and tissue type) and unwanted (sample inde-
pendent) effects, the limma method remove Batch Effects was 
employed to regress out the effect of patient derived variation 
from the matched plasma count.
Sample-weights and log transformation was performed 
using limma package [26] with the voom function used to 
estimate the mean-variance relationship between individual 
observations and then applied to the normalized log-count 
data. Differential expression analysis including, moderated 
F-statistic evaluation, adjusted p-value estimation and Log 
Fold Change (LFC) analysis were performed using a moder-
ated t-test [27] with Benjamini-Hochberg (BH) multiple 
hypothesis test corrections [28]. The data were first pooled 
per gestational age group and then compared. After adjust-
ment, expression of miRNAs was considered significantly 
different at FDR ≤ 0.05. The workflow, source code and 
input files associated with this research available at (https:// 
github.com/mxhp75/earlyPlacentamiRNA_SeqProfile.git).
Results
Characterizing a comprehensive miRNA profile of chorionic 
villous tissue across early gestation to characterize the human 
placental miRNA profile across early to mid gestation, 
Illumina NextSeq 75 bp single-end read sequencing was per-
formed on miRNA libraries from chorionic villous samples 
obtained from 96 singleton pregnancies following elective 
pregnancy terminations (44 females and 52 males bearing 
pregnancies). An average of 18.72 million reads were 
sequenced per sample (range ~10–29 million reads; 
Additional file 1: Table S1). miRNA counts were generated 
by mapping to human miRBase V21 [22]. Libraries with low 
sequencing depth were removed, including samples PAC0131 
(14,595 reads) and PAC0071 (removed due to low mapping 
after initial read count of 1,819,847 reads). Subsequent unsu-
pervised clustering (Additional file 2: Figure S1) using princi-
pal component analysis (PCA) showed eight additional 
samples (PAC0041, PAC0039, PAC0045, PAC0008, 
PAC0035, PAC0024, PAC0034, PAC0006) that segregated 
from the remaining 86 samples, most likely due to the pre-
sence of adjacent non placental villous tissue. This hypothesis 
was tested using matched DNA methylation profiles which 
confirmed the presence of decidual tissue [29], leading to the 
removal of these samples from subsequent analyses.
After filtering, miRNAs were aligned to the human 
GRCh37 reference genome and counts produced from 4,665 
miRBase annotations [22], identifying an initial set of 2,032 
expressed miRNAs. To remove sequencing noise, miRNAs 
with <5 reads across all samples were removed. A total of 
1,422 miRNAs were identified with non-zero expression 
means across all 86 samples, representing a standard known 
miRBase miRNA expression set for early to mid gestation 
human placenta. After accounting for sequencing batch 
effects, very low abundance miRNAs were discarded by con-
verting to log2 CPM values and removing miRNAs with 
expression <2.5 CPM in ≥29 samples (see methods), leaving 
a total of 637 robust miRNAs for downstream profile analyses. 
An additional 588 candidate de novo miRNA sequences were 
predicted through miRDeep2 analysis.
Of the 637 identified miRNAs, the top ten miRNAs with 
the highest mean expression across all samples in placenta 
were miR-30d-5p, miR-125a-5p, miR-517a-3p, miR-199a-3p, 
miR-26b-5p, miR-26a-5p, let-7a-5p, miR-21-5p, miR-126-3p 
and miR-516b-5p (Table 1a). For a full list of miRNAs iden-
tified and profiled in this study see Additional File 1: Table S2. 
A principal component analysis (PCA) of all 637 miRNAs 
(Figure 1) indicates a clear gradient across early gestation. The 
PCA identified 23.2% variance accounted for in PC1, with the 
top 10 miRNAs contributing to PCA dimension one (PC1) 
being: miR-519 c-3p, miR-328-3p, miR-519b-3p, miR-20a-5p, 
miR-19b-3p, miR-501-3p, miR-485-5p, miR-3605-3p and 
miR-515-5p, miR-106a-5p (Additional file 1: Table S3). 
Interestingly both −3p and −5p arms of the miR-20a tran-
script, previously associated with placental angiogenesis [30], 
contributed highly to the gestational age change associated 
with PC1.
Differentially expressed miRNAs across early gestation
Given the importance of oxygen tension in orchestrating the 
growth and differentiation of the placenta between 6 and 
23 weeks’ gestation, we separated the 86 samples in our cohort 
by their gestation relative to the presumed introduction of 
oxygenated maternal blood flow into the intervillous space. 
Using prior knowledge we designated that ≤10 weeks’ (6– 
10 weeks’) gestation be considered pre- and >10 weeks’ (11– 
23 weeks’) gestation be considered post-initiation of maternal 
blood flow into the intervillous space [3]. This enabled us to 
identify changes in miRNA expression across this time-point, 
and to independently assess highly expressed miRNA in each 
group. When miRNAs from all 86 samples were analysed 
according to expression prior to and post 10 weeks’ gestation, 
after accounting for potentially confounding factors such as 
maternal age, maternal BMI, maternal smoking status, we 
identified 13 constitutively expressed miRNAs with consistent 
high expression (log2 CPM 14.35–15.60) in both gestation 
groups (Table 1b). Notably, 4 of the top 20 most highly 
RNA BIOLOGY 3
expressed miRNAs are from the placenta-specific chromo-
some 19 cluster, previously identified as being highly 
expressed in placenta [31–33].
After identifying the highly expressed miRNAs in placenta, 
we then investigated the change in expression that occurs 
after 10 weeks’ gestation once maternal blood flow into the 
placenta is initiated and presumably when oxygen tension 
begins to rise. Differential expression analysis identified 374 
significantly (FDR <0.05) different miRNAs, with 163 down- 
regulated and 211 up-regulated in the 11–23 weeks’ gestation 
placenta compared to 6–10 weeks’ gestation (Figure 2a; 
Additional file 1: Table S4). Strongly downregulated 
miRNAs (negative log2FC) include miR-4483, miR-129-5p, 
miR-124-3p and miR-122-5p, and highest up-regulated (posi-
tive log2FC) include miR-4645-3p, miR-195-3p, miR-137, 
miR-139-3p, miR-6715b-3p, miR-3927-3p and miR-1269b. 
Differentially expressed miRNAs had predominantly low 
expression (Figure 2b) with an average log2 expression >10 
only observed in miR-9-5p (log2FC of −1.43, Figure 2c) and 
let-7a-5p (log2FC of 1.22, Figure 2d). We see that for both let- 
7 and miR-9, the 5ʹ and 3ʹ arms follow a similar expression 
trajectory. Further examples are provided in Additional file 2, 
Figure S2. These mature fragments were originally transcribed 
as a single transcript before further processing (Figure 2e).
Figure 1. Unsupervised clustering of placental chorionic villous samples after batch correction. The PCA plot indicates a clear gestational age gradient from 
early (left) to later gestation (right) in the first dimension. This trend reflects the gestational age signature identified in our miRNA expression data.
Table 1. miRNA with highest expression in early gestation placenta. Global miRNA expression was calculated using the average expression across early gestation 
(6–23 weeks’) and log2 transformed. (a) Top ten miRNA with highest average global expression. (b) Constitutively highly expressed miRNA with membership in the 
top ten by highest average expression if calculated independently for the 6–10 weeks’ and 11–23 weeks’ gestation groups.
a b
miRNA miRNA Family Avg. Global Expression (log2 CPM) miRNA miRNA Family Avg. Expression 
(log2 CPM)
miR-30d-5p miR-30-5p 15.60 6–10 weeks’ 11–23 weeks’
miR-125a-5p miR-125-5p 15.51 miR-30d-5p miR-30d-5p 15.53 15.64
miR-517a-3p miR-517-5p 15.45 miR-125a-5p miR-125-5p 14.93 15.74
miR-199a-3p miR-199-3p 15.43 miR-517a-3p miR-517-5p 15.52 15.40
miR-26b-5p miR-26-5p 15.25 miR-199a-3p miR-199-3p 15.21 15.56
miR-26a-5p miR-26-5p 14.84 miR-26b-5p miR-26-5p^ 15.27 15.21
let-7a-5p let-7-5p/98-5p 14.47 let-7a-5p let-7-5p/98-5p 13.59 14.83
miR-21-5p miR-21-5p/590-5p 14.39 miR-21-5p miR-21-5p/590-5p 14.20 14.59
miR-126-3p None listed 14.31 miR-126-3p None listed 13.91 14.56
miR-516b-5p miR-516b-5p 14.30 miR-516b-5p miR-516b-5p 13.23 14.31
miR-16-5p miR-15-5p/16-5p/195-5p/424-5p/497-5p 14.34 14.32
miR-516a-5p miR-516a-5p 14.40 14.11
miR-143-3p miR-143-3p 13.60 14.52
miR-26a-5p miR-26-5p^ 14.54 14.99
^shared seed region
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Conserved placenta-associated miRNA clusters display 
variable expression between early and mid gestation
In vertebrate species miRNAs are significantly enriched in clus-
ters, with ~50% of miRNA clusters being the result of random or 
non-local duplications. The placenta-associated clusters ana-
lysed herein included chromosome 19 miRNA cluster com-
monly known as C19MC (19q13.41) [34], chromosome 14 
cluster (C14MC; 14q.32) [35], and chromosome 13 cluster 
(miR-17 ~ 92; 13q31.3) with its paralogs the chromosome X 
cluster miR-106a~363 (Xq26.2), and chromosome 7 cluster 
miR-106b~25 (7q22.1) [36]. We identified the expression of 48 
mature miRNAs from C19MC, 77 from C14MC and 20 from 
miR-17 ~ 92 and paralogs. Of the 48 mature miRNAs identified 
in the C19MC cluster, 34 miRNA had significant (FDR <0.05) 
differential expression, that were down regulated in 11– 
23 weeks’ compared to 6–10 weeks’ gestation placenta 
(Additional file 1: Table S5). C19MC cluster expression, as a 
proportion of total miRNA transcripts, was reduced after 
10 weeks’ gestation (Figure 3a). Interestingly, while miRNAs in 
this cluster have been demonstrated to be transcribed by RNA- 
Pol II as a single polycistron [37], the individual members dis-
play a range of expression levels (Figure 3b).
The C14MC cluster, that contains 77 mature miRNAs, 
had 56 miRNAs with significant (FDR <0.05) differential 
expression. 55 of these miRNAs were up-regulated, while 
only one miRNA (miR-410-5p; FDR 1.99 × 10−3) was 
down-regulated in the 11–23 weeks’ gestation group 
(Additional file 1: Table S6). C14MC-member transcript 
expression, as a proportion of total expression, increased 
across early to mid gestation in placenta, further differing 
from C19MC finding by being more centred around the 
group mean (Figure 4a). Similar to C19MC cluster mem-
bers, we found a range of expression levels amongst the 
C14MC members (Figure 4b) that are also thought to be 
transcribed as a single polycistronic transcript, suggesting 
more complex regulation of primary miRNA transcripts 
processing [38]. The miRNA miR-412-5p, previously 
observed as highly expressed in first trimester placenta 
[39], is notable in that it appears to have a bimodal dis-
tribution of expression (Figure 4c) that, upon further inves-
tigation, was not found to be related to sample 
characteristics such as foetal sex, maternal age, maternal 
BMI or maternal smoking status.
Of the 20 mature miRNAs in the miR-17 ~ 92 cluster and 
its paralogs, 17 had significant (FDR <0.05) differential 
Figure 2. Differential expression analysis between 6–10 weeks’ and 11–23 weeks’ gestation placenta. (a) Volcano plot of differential expression. Linear 
regression identified 26 down-regulated with a log2FC <-1 (red) and 26 up-regulated with a log2FC >1 (green) miRNA between gestation groups. (b) MA plot of log2 
fold change as a function of log2 average expression. Box plots of average expression as a function of gestational age for miR-9-5p/3p (c) and let-7a-5p/3p (d) show a 
clear changing pattern of expression from early to mid gestation. (e) Schematic of a representative miRNA hairpin structure indicates the origin of the 5ʹ and 3ʹ arms 
of the mature miRNA transcript.
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Figure 3. The proportion of C19MC transcripts decreased after 10 weeks’ gestation in placenta. The proportion of combined C19MC member expression as a 
function of total miRNA expression is decreased in 11–23 weeks’ compared to 6–10 weeks’ gestation (violin plot) (a) with expression of individual cluster members 
tending to decrease across early to mid gestation (b).
Figure 4. The proportion of C14MC transcripts increased in 11–23 weeks’ compared to 6–10 weeks’ gestation placenta. The proportion of C14MC member 
expression as a function of total miRNA expression is increased after 10 weeks’ gestation compared to 6–10 weeks’ gestation (violin plot) (a). Individual cluster 
members’ expression is increased across early gestation in 55 of the 56 miRNAs (b). miR-412-5p appears to have a bimodal distribution which is unexplained by foetal 
sex, maternal age or maternal smoking status (c).
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expression with 15 being down- and 2 being up-regulated in 
the 11–23 weeks’ gestation group compared to the 6– 
10 weeks’ (Additional file 1: Table S7). Investigation into the 
proportion of placenta expression originating from the miR- 
17 ~ 92 cluster and its paralogs revealed a pattern similar to 
that of the C19MC member transcripts with the proportion of 
transcripts identified in placenta tissue as a function of total 
transcripts decreasing across early gestation (Figure 5(a–c)). 
We identified a variation in expression patterns between each 
of the three paralogs (Figure 5d), with chromosome 13 
expression decreasing across early to mid gestation.
Whilst we find significant (FDR <0.05) differential expres-
sion in all of the above miRNA clusters, the log2FC between 
6–10 weeks’ and 11–23 weeks’ gestation groups is small 
(C19MC log2FC −1.02 to −0.19; C14MC log2FC 0.23 to 0.94 
and log2FC 0.67; miR-17 ~ 92 log2FC −0.2 to −1.13 and log2 
FC 0.84 to 0.89), with changes in the proportional expression 
of each cluster as a function of total miRNA expression 
suggesting an important regulatory mechanism for these clus-
ters in placenta.
Characterizing a comprehensive profile of placental and 
endogenous miRNA in maternal plasma across early 
gestation
To characterize the miRNA profile across early to mid 
gestation in maternal plasma, we sequenced 96 1 to 1 
matched maternal plasma samples (hereafter referred to as 
plasma) from women sampled at the time of pregnancy 
termination using the same sequencing protocol as detailed 
for the chorionic villous tissue. Plasma and tissue samples 
from each termination are assigned a common unique iden-
tifier, with a suffix used to separate sample types. miRNA 
sequencing resulted in approximately 17.77 million 75 bp 
single-end reads per sample in plasma (range 9,986,347– 
41,344,361 reads: Additional file 3: Table S8) across two 
sequencing runs. After initial quality control and sequence 
analysis, we identified a number of samples with aberrant 
expression of miR-451a and miR-16 indicating potential for 
red blood cell miRNA contamination. We performed a 
subsequent analysis using the delta-delta CT method 
(ΔΔCt) to calculate the relative fold change of gene expres-
sion of samples using quantitative polymerase chain reac-
tion (qPCR). The ΔΔCt value of miR-23a minus miR-451 is 
examined, as miR-23a is known to be stable in samples 
affected by haemolysis whilst miR-451 is known to vary 
with contamination. This method identified 11 samples 
(PAC0033, PAC0034, PAC0041, PAC0048, PAC0050, 
PAC0051, PAC0054, PAC0056, PAC0062, PAC0084 and 
PAC0105) as more likely to contain haemolysis contamina-
tion, a common issue in plasma research. Despite potential 
issues involving haemolysis, we aimed to establish the pre-
sence of placenta-specific miRNAs within maternal plasma 
by including all available samples regardless of whether they 
had matched placenta data or not.
Alignment and filtering were performed using the same 
protocol as for chorionic villous tissue. The number of unique 
miRNA species identified per sample varied, ranging from 
1022 miRNA species in PAC0077 to 355 miRNA species in 
PAC0010. Prior to filtering we identified 1775 unique mature 
miRNAs across all plasma samples, with a core set of 790 high 
confidence miRNAs present after filtering. Of these, 531 were 
also present in placenta samples, 259 unique to plasma, and 
106 miRNAs unique to placenta (Additional file 3: Table S9). 
Unsupervised clustering (PCA) of all 790 high confidence 
miRNAs identified in plasma shows no gestational age gradi-
ent for maternal plasma from 6 to 23 weeks’ gestation 
(Additional file 2: Figure S3).
Given the variability of miRNA in plasma, we hypothesized 
that the detection of placental miRNAs in plasma may be 
restricted to miRNA present in high concentrations in 
matched placenta. We therefore investigated whether 10 
miRNAs (Table 1a) with the highest abundance in placenta 
were present in plasma and found that all ten miRNA were at 
high abundance levels in matched plasma (Figure 6, Table 2a). 
Many of the most highly expressed plasma miRNA are red 
blood cell (RBC) associated.
Of the 790 miRNAs identified in plasma, the top ten 
miRNAs with the highest global expression were miR-16-5p, 
miR-486-5p, miR-92a-3p, let-7a-5p, let-7b-5p, miR-451a, let- 
7 f-5p, miR-25-3p, let-7i-5p, miR-93-5p (Table 2b). These 
were also all highly expressed in placental tissue (average 
global expression of 8.95–14.47 Log2 normalized CPM). 
miR-141, miR-200b, miR-139 and miR-184, previously iden-
tified in third trimester plasma, were also identified at high 
abundance in our early gestation plasma, with miR-141-3p 
abundance increasing across early gestation, as shown in pre-
vious studies [40].
We investigated plasma levels of the 21 miRNAs identi-
fied as both differentially and highly expressed in the 
matched placentas (Table 3). Whilst all 21 placental 
miRNAs were also detected in plasma, their origin is not 
necessarily placenta-specific, with cellular enrichment 
linked to various systemic compartments [41]. For example, 
five of these miRNAs have cellular enrichment in immune 
response, another three miRNAs in pluripotent and 
embryonic stem cells, and one miRNA is enriched in extra- 
embryonic stem cells. The latter may originate from the 
foetal membranes or other extra-embryonic tissue such as 
chorionic villi.
We further investigated the abundance of plasma miRNAs 
from three miRNA clusters previously identified as highly 
placenta-specific or placenta associated [34–36]. We found 
44 mature miRNA from the C19MC cluster, 48 miRNA 
from the C14MC cluster and 20 miRNA from the miR- 
17 ~ 92 cluster and its paralogs in plasma. These cluster 
miRNAs have previously been the target of biomarker 
research in pregnancy health but to our knowledge these are 
not being used clinically.
The change in relative proportion of expression by miRNA 
cluster members in plasma across the 10–11 weeks’ gestation 
threshold is difficult to detect with C14MC and C19MC 
members each representing less than 1% of the miRNA abun-
dance quantified in plasma. As such the proportional change 
identified in placenta is not entirely reflected in plasma. 
Abundance levels of the miR-17 ~ 92 cluster and its paralogs 




In this study, we have assessed the miRNA profile of 96 
human placenta and matched plasma samples in early to 
mid gestation (6–23 weeks’), generating a placental tissue 
dataset using high-throughput sequencing that is substantially 
larger than previous reports that used microarray and qPCR 
profiling. We derive robust and comprehensive profiles that 
define miRNA expression at high-resolution, applying strin-
gent bioinformatic protocols for the analysis of sequencing 
data, akin to large atlas studies.
Differentially expressed miRNAs reflect the dynamically 
changing utero-placental environment during early to 
mid gestation
In order to determine the potential association between pla-
cental miRNA expression and pregnancy health, particularly 
the expression of highly abundant miRNAs across early gesta-
tion, we examined more closely a period in early gestation 
involving a steep rise in oxygen tension in the intervillous 
space (IVS). Rising oxygen tension occurs between 10 and 
12 weeks’ gestation, at the onset of maternal blood flow into 
the IVS, resulting in an oxidative burst in placenta [3]. 
Previous studies have addressed miRNA response to hypoxia 
and the introduction of oxygen [42–46], including how ecto-
pic oxygen tension may contribute to diseases of pregnancy 
[42,47–49]; and reviewed in [50]. The number and extensive 
gestation range of our samples enabled us to analyse the 
differential expression of miRNAs prior to, during and post 
the critical 10–11 weeks’ gestational time point. This has 
potential to lead to identification of placental mechanisms 
for the remediation of oxidative stress at this crucial time in 
pregnancy.
That the placenta develops initially in a condition of low 
(but physiological) oxygen tension has been known for some 
time [3], and it has been suggested that this is important for 
the protection of the early foetus from the effects of oxidative 
stress such as tissue damage from oxygen free radicals [51]. 
miRNAs are uniquely poised to play a significant role in the 
mediation of gene expression throughout the early change of 
oxygen tension in the placenta by employing post transcrip-
tional regulatory mechanisms to rapidly and precisely fine 
tune the placental environment in response to oxidative stress. 
We identified upregulation of let-7b/e-5p, miR-21, miR-23a/ 
b-3p, miR-24-3p and miR-199a-5p, also associated with 
HIF1ɑ, in the 6–10 weeks’ gestation group. All of these have 
previously been shown to be upregulated by hypoxia. We also 
found lower abundance of let-7a and miR-101-3p in our 6– 
10 weeks’ gestation group, both of which have previously been 
shown to be downregulated by hypoxia [52–56]; and reviewed 
in [57]. miRNAs identified in this study likely play an impor-
tant role in the mitigation and regulation of hypoxia in the 
placenta. This may prove important to our understanding of 
diseases of pregnancy such as preeclampsia and early preg-
nancy loss.
The importance of miRNA function in the early placenta is 
not limited to the mitigation of oxidative stress but also in 
Figure 5. The proportion of miR-17 ~ 92 (Chr 13) and paralogs 106b~25 (Chr 7) and 106a~363 (Chr X) transcripts decreased in 11–23 weeks’ compared to 
6–10 weeks’ gestation placenta. Violin plot showing decreased proportion of miR-17 ~ 92 member expression as a function of total miRNA expression after 
10 weeks’ gestation (a, b, c) with a general trend of decreased expression of individual cluster members across early gestation (d). Although chromosome 13 and 
chromosome X appear correlated, expression of miR-17 ~ 92 (chromosome 13) and its paralogs miR-106a~363 (chromosome 7) and miR-106b~25 (X chromosome) 
does not appear to follow a common expression pattern in placental tissue as we would expect if all 3 clusters are identically regulated by C-Myc.
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cellular proliferation, trophoblast invasion and cellular differ-
entiation, which are important to the placenta and also to the 
success of the pregnancy. let-7a-5p expression in first trime-
ster placental explants has been implicated in a reduction in 
cytotrophoblast proliferation. In our differential expression 
analysis we identified let-7a-5p as up-regulated in the 11– 
23 weeks’ gestation compared to the 6–10 weeks’ gestation 
group. Our detailed week-by-week expression data suggests 
an incremental increase across early to mid gestation which 
together with previous term data is consistent with let-7a-5p’s 
proposed role in regulation of placental growth by the reduc-
tion of cytotrophoblast proliferation [58]. The miR-34 family 
is known as a tumour suppressor miRNA family due to their 
synergistic effects with p53 [59]. Consistent with this, we 
Table 2. miRNA by average expression in maternal plasma. Average miRNA expression was calculated using the average normalized CPM expression across early 
to mid gestation (6–23 weeks’) and log2 transformed. (a) All top 10 miRNA with highest abundance in placenta were also detected at high abundance in plasma. 
Two miRNA (miR-517a-3p and miR-516b-5p) originate from the C19MC. (b) Top 10 miRNA by abundance in maternal plasma. RBC-associated miRNA identified herein 
have been previously identified in plasma samples including adult plasma and umbilical cord plasma but have not previously been profiled extensively in maternal 
plasma in early to mid gestation.
a b
miRNA miRNA Family Avg. Global Expression (log2 CPM) miRNA miRNA Family Avg. Global Expression 
(log2 CPM)
miR-30d-5p miR-30-5p 13.35 miR-16-5p+ miR-15-5p/16-5p/195-5p/424-5p/497-5p 18.23
miR-125a-5p miR-125-5p 10.59 miR-486-5p+ miR-486-5p 17.46
miR-517a-3p^ miR-517-5p 4.71 miR-92a-3p+ miR-25-3p/32-5p/92-3p/363-3p/367-3p 16.22
miR-199a-3p miR-199-3p 10.62 let-7a-5p let-7-5p/98-5p 15.70
miR-26b-5p miR-26-5p 12.84 let-7b-5p let-7-5p/98-5p 15.55
miR-26a-5p miR-26-5p 12.70 miR-451a+ miR-451 14.42
let-7a-5p let-7-5p/98-5p 15.70 let-7 f-5p let-7-5p/98-5p 14.15
miR-21-5p miR-21-5p/590-5p 12.87 miR-25-3p miR-25-3p/32-5p/92-3p/363-3p/367-3p 13.97
miR-126-3p None listed 13.41 let-7i-5p let-7-5p/98-5p 13.92
miR-516b-5p^ miR-516b-5p 4.27 miR-93-5p miR-17-5p/20-5p/93-5p/106-5p/519-3p 13.58
^ C19MC + RBC
Table 3. The abundance in plasma of miRNA differentially expressed in matched placenta. Average miRNA expression was calculated using the average CPM 








Compartment of origin* Cellular enrichment^
let-7a-5p 1.24 14.27 15.70 brain, epididymis, spinal cord Mesodermal cells
miR-542-5p 1.11 7.07 0.66 epididymis, small intestine, lymph 
node
None listed
miR-222-3p 1.00 9.66 6.51 bladder, epididymis, prostate Endothelial cell, endothelial cell of vascular tree, blood vessel endothelial
miR-1-3p 1.00 7.20 4.45 muscle, myocardium Muscle, skeletal muscle, mesodermal cell
miR-199b-5p 0.97 10.24 2.72 colon, epididymis, oesophagus, skin, 
thyroid, vein
Fibroblast, mesodermal cell
miR-99a-5p 0.98 8.57 5.92 Arachnoid mater, brain, epididymis, 
prostate, spinal cord
Mast cell, leukocyte, myeloid leukocyte
miR-223-3p 0.99 10.93 13.28 vein Leukocyte, haematopoietic cell, myeloid leukocyte
miR-221-3p 0.94 13.13 9.65 Epididymis, prostate Endothelial cell, ciliated epithelial cell, muscle cell
miR-100-5p 0.98 12.83 5.58 Arachnoid mater, nerve, spinal cord, 
brain
Muscle cell, smooth muscle cell, vascular associated smooth muscle cell
miR-181a-5p 0.94 13.06 10.09 Arachnoid mater, brain, dura mater, 
spinal cord
Leukocyte, haematopoietic cell, B cell
miR-363-3p 0.94 9.18 9.26 Epididymis, vein Leukocyte, haematopoietic cell, lymphocyte
miR-122-5p −2.53 6.74 13.09 Liver, vein Hepatocyte, endodermal cell
miR-9-5p −1.42 10.51 2.19 Brain, spinal cord Neural cell, neuroectodermal cell, ectodermal cell
miR-9-3p −1.37 6.79 −2.25 Brain, dura mater, spinal cord None listed
miR-372-3p −1.08 8.17 −2.98 No profile Pluripotent stem cell, embryonic stem cell, induced pluripotent stem cell, 
depleted in extraembryonic stem cell
miR-371a-5p −1.01 7.90 −2.81 Constitutive expression Pluripotent stem cell, embryonic stem cell, induced pluripotent stem cell, 
depleted in extraembryonic stem cell
miR-520 f-3p −0.98 6.86 −3.07 spleen Pluripotent stem cell, embryonic stem cell, induced pluripotent stem cell, 
depleted in extraembryonic stem cell
miR-934 −0.93 9.32 −2.44 Constitutive expression, highest in 
gallbladder and pleura
Epithelial cell, extraembryonic cell, endo-epithelial cell
miR-20a-5p −0.85 10.02 9.73 Constitutive expression, highest in 
vein
Pluripotent stem cell, epithelial cell, endothelial cell
miR-17-5p −0.77 6.80 8.77 Constitutive expression, highest in 
vein
Epithelial cell, pluripotent stem cell, endothelial cell




identified up-regulation of all six miR-34 family members 
reflecting a reduction in cellular proliferation as the preg-
nancy progresses and placental growth trajectory begins to 
slow. Similarly, miR-378a-5p was previously found to enhance 
cell survival and promote trophoblast migration and invasion 
[60]. Our data showed significant down-regulation of the 
miR-34 family in 11–23 weeks’ gestation compared to the 6– 
10 weeks’ gestation placenta potentially linking down- 
regulation of these miRNAs with the reduced trophoblast 
migration as pregnancy progresses. miR-200 family members 
are also known to have an established role in placental func-
tion, in particular in the cellular transition from epithelial to 
mesenchymal (EMT) phenotype which is a prerequisite for 
extravillous trophoblast invasion of the maternal decidua. 
miR-200 family members play a well-known role in EMT 
through a feedback loop with the ZEB family of transcription 
factors. We identified seven members of the miR-200 family, 
six of which are down-regulated in the 11–23 weeks’ gestation 
group. The miR-200 family is known to be highly expressed in 
epithelial cell types [61] and thus its down-regulation is con-
sistent with development of the vascularized mesenchymal 
core in chorionic villi in the second trimester.
Proportional change in expression miRNA clusters play a 
role in placenta gene regulation during development
miRNA clusters are known to play an important role in the 
placenta, with these regions thought to have co-evolved and to 
act cooperatively to repress target genes [62]. Interestingly, 
while miRNA clusters are typically transcribed as a single 
polycistronic transcript, we identified large intra-sample var-
iances in the expression levels of cluster members (Additional 
file 2, Figure S4) hinting at additional post transcriptional 
regulatory mechanisms. There are a number of miRNA clus-
ters expressed either exclusively, or preferentially in placenta 
[31,63,64]. In particular, the C19MC, C14MC and miR- 
17 ~ 92 clusters have been shown to regulate phenotypic 
and functional diversity in frequently used cell lines and 
isolated primary trophoblasts, and in the immune system, by 
which they may play a role in immune tolerance to paternal 
antigens [32,65,66].
C19MC is expressed almost exclusively in the placenta 
but also in certain tumours and undifferentiated cells 
[34,67]. C19MC is a large placenta specific imprinted cluster 
located on chromosome 19q13.41 and mono-allelically 
Figure 6. Abundance of maternal plasma miRNAs, identified as highly expressed in chorionic villous tissue, from 6–23 weeks’ gestation. All ten miRNAs 
identified as the most highly expressed in chorionic villous tissue were identified as highly abundant in matched plasma samples. Abundance of the C19MC miRNA 
members, miR-516b-5p and miR-517a-3p, appear to increase across early to mid gestation.
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expressed from the paternally inherited chromosome [68]. 
This cluster has been difficult to study as its expression is 
both placenta and primate specific [68] and hence lacks an 
ortholog in mouse [35]. Importantly, C19MC members are 
expressed at lower than trophoblast levels in JEG-3 and JAR 
cells, two cell lines derived from choriocarcinoma [69], and 
are not expressed in the commonly used HTR8/SVneo cell 
line [64,67] highlighting the need for primary placental 
tissue in research. Consistent with our findings, previous 
research has shown that C19MC constitutes a large propor-
tion of total miRNA transcripts (15% at term), with our data 
additionally showing a gestational decline from 27% at 6– 
10 weeks’ gestation to 23% at 11–23 weeks’ gestation [33,67]. 
In addition, there was a significant (FDR < 0.05) down- 
regulation in 34 C19MC cluster members in 11–23 weeks’ 
placenta compared to the 6–10 weeks’ gestation. 
Interestingly, a previous report showed that 46 of the 47 
miRNAs from the C19MC cluster were up-regulated in third 
trimester villous trophoblasts compared to first trimester 
[32]. It is possible that this miRNA cluster exhibits a 
dynamic gestational expression pattern but perhaps more 
likely is the possibility that differences between studies can 
be explained by differences in expression between assess-
ment of trophoblast versus whole chorionic villous tissue. 
The latter is more physiologically relevant and fits our ques-
tion. However, this also introduces the question of whether 
the changes we see are due at least in part to the change in 
cell type proportions seen in the placenta throughout gesta-
tion [70].
A recent miR-517a/c in situ hybridization analysis loca-
lized expression from these C19MC miRs to cytotrophoblast 
and syncytiotrophoblast in chorionic villi, proximal cytotro-
phoblasts in anchoring villi, decreased expression in distal 
cytotrophoblasts with further reduction in extra-villous cyto-
trophoblasts. This finding highlights variable expression of 
the C19MC cluster in different placental cell types, and 
shows loss of expression of this cluster as trophoblasts differ-
entiate to extravillous phenotypes post EMT [71]. Another 
report concurs showing higher expression of C19MC mem-
bers in villous trophoblasts compared to extravillous tropho-
blasts suggestive of a role for the C19MC cluster miRNA in 
attenuation of EVT migration through the direct targeting of 
mRNA transcripts related to cellular movement [72]. 
Mouillet et al. (2015) suggested a role for C19MC in cellular 
differentiation or the maintenance of pluripotency [73]. 
Further investigation into the proportional change in expres-
sion from pregnancies complicated by placental pathology 
may help to identify miRNA species with biomarker poten-
tial in plasma. However, low expression levels in some 
maternal plasma samples have frustrated our efforts in this 
regard.
C14MC, located at the imprinted DLK1-DIO3 domain on 
human chromosome 14q32 is the largest known human 
miRNA cluster comprising 52 miRNA genes expressed from 
the maternally inherited chromosome [64]. The C14MC clus-
ter is found exclusively in eutherian mammals and has been 
suggested to be essential to the evolution of this lineage, with 
expression in humans demonstrating a strong bias towards 
brain, placenta and some embryonic tissues [63]. Our analysis 
identified expression from 84 mature miRNAs in the C14MC 
cluster with the proportion of member transcripts increased 
in the 11–23 weeks’ gestation group compared to 6–10 weeks’ 
gestation. Previous studies investigating C14MC expression, 
in both whole villous tissue and in primary cytotrophoblasts, 
have reported a decrease in expression from first to third 
trimester. Using whole villous tissue, Gu et al. (2013) [74] 
identified 11 miRNA from this cluster down-regulated in 
third compared to first trimester, and proposed a link between 
both C19MC and C14MC in immune suppression and innate/ 
adaptive immune response in the mother. In primary cyto-
trophoblast, Morales-Prieto et al. (2012) [32] identified 34 
miRNA from this cluster which were also down-regulated in 
third compared to first trimester [64,74]. Whilst the discre-
pancy between our data and Morales-Prieto et al. (2013) can 
be explained by the use of different biological source (single 
cell type versus whole tissue), that between our data and Gu et 
al. (2013) is not so clear but may be due to differences in 
technology, the number of cluster members identified, or that 
our samples range up to 23 weeks’ gestation and do not 
include term. It is plausible that rather than a steady decline 
from early gestation to term, the expression of C14MC mem-
bers increases across early gestation, before decreasing at 
term. Consistent with a recent report by Wommack et al. 
(2018) [75] who profiled circulating miRNAs in maternal 
plasma and found an inverse relationship between placenta- 
specific clusters C19MC and C14MC we found this in our 
tissue samples.
Finally, in the analysis of placenta-associated clusters we 
investigated the expression of miR-17 ~ 92 and paralogs miR- 
106a~363 and miR-106b~25, identifying 19 mature miRNAs. 
The proportion of total expression from miR-17 ~ 92 mem-
bers and paralogs are less than 1% per cluster, with all three 
clusters showing an overall decrease in the proportion of total 
expression across early to mid gestation. Using the miRNA 
sequences provided by Kumar et al. (2013) [65], we deter-
mined the 5ʹ or 3ʹ origin of the transcripts by cross-checking 
the given sequences against miRBase v21 [23,65], and were 
thus able to directly compare their microarray data with our 
sequencing data (detailed in Additional File 3: Table S11).
Plasma miRNA sequencing offers a potential source of 
non-invasive biomarkers for detecting placenta health
In addition to establishing the placental miRNA profile across 
early to mid gestation and, given the potential for placental 
health biomarker discovery using our access to matched 
maternal plasma, we also aimed to analyse miRNA profiles 
in maternal plasma sampled in women at the same time as 
placenta. The identification of placenta-derived, or preg-
nancy-associated miRNA in plasma offers a potential window 
into minimally invasive monitoring of pregnancy progression.
Working with miRNA in plasma is known to be difficult 
due to potential inclusion of red blood cells or other cellular 
debris [76–78]. Red blood cell contamination may mask any 
signal we hoped to detect from the placenta as haemolysis 
may perturb miRNA species and count distributions due to 
overloading of red blood cell miRNAs [76,78,79]. In our study 
we see evidence that 11 of our samples were likely affected by 
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haemolysis. This common difficulty with plasma data, led us 
to assess the detection of miRNAs of interest revealing that 
the 10 most abundant placental miRNAs were reflected by 
high abundance levels in matched plasma. Furthermore, these 
plasma miRNAs in our study show strong concordance with 
previous miRNA plasma studies [77,80].
Differential expression and clear gestational age gradient 
clustering patterns in placenta miRNAs between 6–10 and 11– 
23 weeks’ gestation were not particularly reflected by maternal 
plasma, indicating that plasma does not reflect the changes in 
the miRNA profile in placenta across early to mid gestation. 
miRNAs that were abundant in placenta were not always 
found to be abundant in plasma. In particular, miRNAs 
enriched in Pluripotent stem cell/embryonic stem cell were 
of low abundance in plasma compared to placenta. With the 
exception of placenta-specific miRNAs, cellular enrichment 
could be linked to various other systemic compartments. For 
example, five miRNAs have cellular enrichment in immune 
response cells, whilst another three miRNAs have enrichment 
in pluripotent and embryonic stem cells, and one miRNA is 
enriched in extra-embryonic stem cells which may originate 
from the foetal membranes or other extra-embryonic tissue 
such as chorionic villi. Of particular interest, miR-99a-5p 
enrichment includes enrichment in mast cells which are 
involved in inflammatory response and allergic reactions. 
We see an apparent increase in abundance of miR-99a-5p 
across early to mid gestation, and some additional increase 
in male- compared with female-bearing pregnancies, which 
may be indicative of the increased maternal immune response 
to the male conceptus [81].
Complementary to the investigation of miRNA clusters in 
placenta, we also investigated the expression of three highly 
placenta-associated miRNA clusters and confirmed the abun-
dance of these cluster miRNAs in plasma, with the proportion 
of cluster member expression revealing biomarker potential in 
plasma. One pathway for the transfer of placental molecules 
into the maternal circulation is via exosomes. It has previously 
been reported that members of the C19MC are the predomi-
nant miRNA species expressed in exosomes released from 
primary human trophoblasts [67]. We were able to confirm 
the presence of 39 C19MC, 48 C14MC and 20 miR-17 ~ 92 
miRNA in matched plasma, with their presence showing 
promise for the use of miRNA as biomarkers for placental 
health. Perhaps more importantly, week-by-week examination 
of miRNAs across early gestation, as described in this study, 
are key elements for developing pregnancy surveillance mea-
sures in the future, especially when combined with disease- 
specific profiles associated with preeclampsia, gestational dia-
betes and preterm birth. Our investigation here of miRNAs as 
biomarkers of placental, and by proxy pregnancy health have 
identified many areas for further investigation. With the 
implementation of machine learning algorithms, cell free 
DNA work and placenta specific analysis standards, much 
more can be expected from this field.
Conclusion
Appropriate placental growth and development is essential for 
pregnancy success and miRNAs play roles in mediating these. 
We investigated placental and maternal plasma miRNAs using 
matched samples taken after elective termination of otherwise 
normal pregnancies and found 374 significantly (FDR <0.05) 
differentially expressed miRNA between 6–10 and 11– 
23 weeks’ gestation placenta.
The research conducted herein is the most comprehensive 
attempt to accurately profile the miRNA landscape of the 
human placenta, in part, because of the use of miRNA sequencing 
rather than microarray or qPCR. This dataset represents unpre-
cedented access to a large number of human placenta samples 
from 6–23 weeks of gestation. Together these data are an impor-
tant reference set for miRNA expression of early to mid gestation 
placental development and function, at time points rarely seen in 
previous placental sequencing work. These provide an important 
resource for the placental biology field. Further investigation using 
maternal plasma in early gestation samples from pregnancies with 
known outcomes will provide further insights into the search for 
miRNAs as biomarkers of pregnancy health and disease.
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